Moldable, curable, osteoinductive bone matrix

Self-setting calcium phosphate matrix with engineered allograft bone particles for optimized compressive strength and resorptive characteristics.

Product Overview

TRABEXUS EB is a proprietary, biocompatible, self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles. Partial demineralization of allograft has been shown to expose key osteoinductive proteins that can influence and direct bone repair.

TRABEXUS EB is supplied as a multi-component, sterile, single use kit. After briefly mixing the product components at the point of use, the material will transform into a paste and remain workable for up to 4.5 minutes. Upon setting, the calcium phosphate component will convert to hydroxyapatite, the mineral composition of native human bone. TRABEXUS EB is resorbed and remodeled by the body as new bone formation occurs during the healing process.

TRABEXUS EB is intended for use to fill bony voids or defects of the skeletal system (i.e. extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone.


The Science of Engineered Bone

The cornerstone of TRABEXUS EB is the thoughtful design of the allograft component. In TRABEXUS EB, the allograft component is formed into “hourglass” shapes (known as TRABS®) using a proprietary manufacturing process. This novel shape provides multiple benefits, including increased “interconnectivity” of adjacent particles, creation of channels for accelerated remodeling and greater overall surface area. These factors optimize the ratio of compressive strength to allograft content. The TRABS are partially demineralized, exposing key osteoinductive proteins, while preserving a core of mineralized cortical bone allograft, which further optimizes the product’s resorption characteristics.




Additional Performance Characteristics

Composition Resorbable calcium phosphate matrix with partially demineralized allograft particles “TRABS”
Compressive Strength Up to 25MPa
Osteoconductive Material crystallizes into hydroxyapatite upon setting, the mineral phase of native human bone
Osteoinductive Allograft component is partially demineralized, exposing key osteoinductive proteins
Resorption Profile More rapid compared to calcium phosphate cements
Thermal stability Does not require refrigeration prior to use
Resistant to lavage Solidifies in a wet field
Sizes 3cc, 5cc, 10cc

TRABEXUS EB is covered by United States patent 9,072,720, with additional patents pending.

Allograft component demonstrated osteoinducivity in athymic mouse model submitted for 510(k). Refer to 510(k) summary K143547. Data on file at Vivorté, Inc.